Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07209813) titled 'GKL-006 Combined With TACE in Treatment of Unresectable Hepatocellular Carcinoma' on Sept. 29.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Beijing Gene Key Life Technology Co., Ltd
Condition:
Hepatocellular Carcinoma
Intervention:
Biological: GKL-006
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: October 12, 2025
Target Sample Size: 48
To know more, visit https://clinicaltrials.gov/study/NCT07209813
Disclaimer: Curated by HT Syndication....